# EDGAR Filing Document

**Accession Number:** 0001757898
**File Stem:** 0001193125-25-139956
**Filing Date:** 2025-6
**Character Count:** 7180
**Document Hash:** 7730f78d9eb6cb714d11e0bce20fc40e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-139956.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001193125-25-139956

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** STERIS plc
- **CENTRAL INDEX KEY:** 0001757898
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38848
- **FILM NUMBER:** 251043110

**BUSINESS ADDRESS:**
- **STREET 1:** 70 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN
- **STATE:** L2
- **ZIP:** 2
- **BUSINESS PHONE:** 35312322000

**MAIL ADDRESS:**
- **STREET 1:** 70 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN
- **STATE:** L2
- **ZIP:** 2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STERIS Ltd
- **DATE OF NAME CHANGE:** 20181101

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14A** 

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

**(Amendment No.)** 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only as permitted by Rule 14a-6(e)(2))** 

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to § 240.14a-12

**STERIS plc** 

**(Name of Registrant as Specified in its Charter)** 

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)** 

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(l) and 0-11.

------

![LOGO](g565169dsp02a.jpg)

You invested in STERIS plc and it's time to vote!

You have the right to vote on proposals being presented at the Annual General Meeting. **This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on July 31, 2025.**

Get informed before you vote

View the Notice and Proxy Statement, Fiscal 2025 Annual Report, and Directors' Report and Consolidated Financial Statements for the Year Ending March 31, 2025 online OR you can receive a free paper or email copy of the material by requesting prior to July 17, 2025. If you would like to request a copy of the material for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

![LOGO](g565169dsp02b.jpg)

\*Please check the meeting materials for any special requirements for meeting attendance and instructions on how to request directions to the meeting. At the meeting, you will need to request a ballot to vote these shares.

------

**Vote at www.ProxyVote.com** 

**THIS IS NOT A VOTABLE BALLOT** 

This is an overview of the proposals being presented at the

upcoming shareholder meeting. Please follow the instructions on

the reverse side to vote these important matters.

---

| | | |
|:---|:---|:---|
| **Voting Items** | **Board<br>Recommends** | **Board<br>Recommends** |
| 1. Election of Directors |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Nominees:** <br>|  |  |
|  1a. Dr. Esther M. Alegria | ![LOGO](g565169g03s01.jpg)  | **For** |
|  1b. Richard C. Breeden | ![LOGO](g565169g03s01.jpg)  | **For** |
|  1c. Daniel A. Carestio | ![LOGO](g565169g03s01.jpg)  | **For** |
|  1d. Cynthia L. Feldmann | ![LOGO](g565169g03s01.jpg)  | **For** |
|  1e. Christopher S. Holland | ![LOGO](g565169g03s01.jpg)  | **For** |
|  1f. Paul E. Martin | ![LOGO](g565169g03s01.jpg)  | **For** |
|  1g. Dr. Nirav R. Shah | ![LOGO](g565169g03s01.jpg)  | **For** |
|  1h. Louis A. Shapiro | ![LOGO](g565169g03s01.jpg)  | **For** |
|  1i. Dr. Mohsen M. Sohi | ![LOGO](g565169g03s01.jpg)  | **For** |
|  1j. Dr. Richard M. Steeves | ![LOGO](g565169g03s01.jpg)  | **For** |
| 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending March 31, 2026. | ![LOGO](g565169g03s01.jpg)  | **For** |
| 3. To appoint Ernst & Young Chartered Accountants as the Company's statutory auditor under Irish law to hold office until the conclusion of the Company's next annual general meeting. | ![LOGO](g565169g03s01.jpg)  | **For** |
| 4. To authorize the Board of Directors of the Company or the Audit Committee of the Board of Directors to determine the remuneration of Ernst & Young Chartered Accountants as the Company's statutory auditor under Irish law. | ![LOGO](g565169g03s01.jpg)  | **For** |
| 5. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed pursuant to the disclosure rules of the U.S. Securities and Exchange Commission, including the compensation discussion and analysis and the tabular and narrative disclosure contained in the Company's proxy statement dated June 12, 2025. | ![LOGO](g565169g03s01.jpg)  | **For** |
| 6. To approve a proposal renewing the Board of Directors' authority to issue shares under Irish law. | ![LOGO](g565169g03s01.jpg)  | **For** |
| 7. To approve a proposal renewing the Board of Directors' authority to opt-out of statutory pre-emption rights under Irish law. | ![LOGO](g565169g03s01.jpg)  | **For** |
| 8. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. | 8. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. |  |

---

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;V76058-P33101-Z90123